Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
Wave Life Sciences announces encouraging 6-month data from the Phase 1 portion of its INLIGHT trial evaluating WVE-007, an investigational RNAi therapeutic for obesity. A single 240 mg dose demonstrated significant reductions in visceral fat and waist circumference, preservation of lean muscle, and a favorable safety profile. These results surpass …